Bibliography
- Dalhoff A , UllmannU: Correlation between pharmacokinetics, pharmacodynamics and efficacy of antibacterial agents in animal models.Eur. J. Clin. Microbiol. Infect. Dis.9, 479–487(1990).
- Wang JC : DNA topoisomerases.Annu. Rev. Biochem.65, 635–692(1996).
- Wang JC , LynchAS: Transcription and DNA supercoiling.Curr. Opin. Genet. Dev.3, 764–768(1993).
- Pan XS , FisherLM: Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.Antimicrob. Agents Chemother.41, 471–474(1997).
- Zechiedrich EL , CozzarelliNR: Roles of topoisomerase IV and DNA gyrase in DNA unlinking during replication in Escherichia coli.Genes Dev.9, 2859–2869(1995).
- Kato J , SuzukiH, IkedaH: Purification and characterization of DNA topoisomerase IV in Escherichia coli.J. Biol. Chem.267, 25676–25684(1992).
- Blondeau JM : Fluoroquinolones: mechanism of action, classification, and development of resistance.Surv. Ophthalmol.49(Suppl. 2), S73–S78 (2004).
- Hooper DC : Mechanisms of action of antimicrobials: focus on fluoroquinolones.Clin. Infect. Dis32(Suppl. 1), S9–S15 (2001).
- Hooper DC : Emerging mechanisms of fluoroquinolone resistance.Emerging Infect. Dis.7, 337–341(2001).
- Sierra JM , CabezaJG, Ruiz Chaler M et al.: The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae. Clin. Microbiol. Infect.11, 750–758(2005).
- Hooper DC : Fluoroquinolone resistance among Gram-positive cocci.Lancet Infect. Dis.2, 530–538(2002).
- Noreddin AM , HobanDJ, ZhanelGG: Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae.Int. J. Antimicrob. Agents26, 120–125(2005).
- MacDougall C , HarpeSE, PowellJP, JohnsonCK, EdmondMB, PolkRE: Pseudomonas aeruginosa, Staphylococcus aureus and fluoroquinolone use.Emerging Infect. Dis.11, 1197–1204(2005).
- Dalhoff A , Schmitz F-J: In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur. J. Clin. Microbiol. Infect. Dis.22, 203–221(2003).
- Hoogkamp-Korstanje JA : In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.J. Antimicrob. Chemother.40, 427–431(1997).
- Jones RN , SaderHS, BeachML: Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997–2001).Int. J. Antimicrob. Agents22, 551–556(2003).
- Reinert RR , ReinertS, van der Linden M, Cil MY, Al-Lahham A, Appelbaum P: Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003. Antimicrob. Agents Chemother.49, 2903–2913(2005).
- Yamaguchi K , OhnoA: Investigation of the susceptibility trends in Japan to fluoroquinolones and other antimicrobial agents in a nationwide collection of clinical isolates: a longitudinal analysis from 1994 to 2002.Diagn. Microbiol. Infect. Dis.52, 135–143(2005).
- Mikamo H , KawazoeK, SatoY, IzumiK, TamayaT: Therapeutic effects of a new quinolone, DU-6859a, on polymicrobial infections in a newly designed model of rat uterine endometritis.J. Antimicrob. Chemother.41, 131–133(1998).
- Montanari MP , MingoiaM, MarchettiF, VaraldoPE: In vitro activity of levofloxacin against gram-positive bacteria.Chemotherapy45, 411–417(1999).
- Zhanel GG , NoreddinAM: Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections.Curr. Opin. Pharmacol.1, 459–463(2001).
- Lacy MK , LuW, XuXet al.: Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection.Antimicrob. Agents Chemother.43, 672–677(1999).
- Lister PD : Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae.Diagn. Microbiol. Infect. Dis.44, 43–49(2002).
- Noreddin AM , MarrasTK, SandersK, ChanCK, HobanDJ, ZhanelGG: Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP).Int. J. Antimicrob. Agents24, 479–484(2004).
- Hoban D , BaqueroF, ReedV, Felmingham D: Demographic analysis of antimicrobial resistance among Streptococcus pneumoniae: worldwide results from PROTEKT 1999–2000. Int. J. Infect. Dis.9, 262–273(2005).
- Drusano GL , PrestonSL, FowlerC, Corrado M, Weisinger B, Kahn J: Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J. Infect. Dis.189, 1590–1597(2004).
- Biedenbach DJ , MoetGJ, JonesRN: Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997–2002).Diagn. Microbiol. Infect. Dis.50, 59–69(2004).
- Levaquin® package insert. Ortho McNeil Pharmaceutical Corporation, Raritan, NJ, USA (2005).
- File TM Jr, Segreti J, Dunbar L et al.: A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob. Agents Chemother.41, 1965–1972(1997).
- Dunbar LM , WunderinkRG, HabibMPet al.: High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin. Infect. Dis.37, 752–760(2003).
- Shorr AF , ZadeikisN, KhashabMM, TennenbergAM, Wes Ely E: Levofloxacin 750-mg, 5-day therapy for community-acquired pneumonia. Outcomes in the elderly American Thoracic Society International Conference. Orlando, FL, USA (2004) (Abstract 505).
- Fogarty C , SiamiG, KohlerRet al.: Multicenter open-label randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin-clavulanate in the treatment of serious community-acquired pneumonia in adults.Clin. Infect. Dis.38, S16–S23 (2004).
- Anzueto A , NiedermanMS, PearleJet al.: Community-acquired pneumonia recovery in the elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.Clin. Infect. Dis.42, 73–81(2006).
- Zervos M , MandellLA, VroomanPSet al.: Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia.Treat. Respir. Med.3, 329–336(2004).
- Leroy O , SauxP, Bedos J-P, Caulin E: Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest128, 172–183(2005).
- Sabria M , Pedro-BotetML, GomezJet al.: Fluoroquinolones vs macrolides in the treatment of legionnaires disease.Chest128, 1401–1405(2005).
- Mykietiuk A , CarratalàJ, Fernández-SabéNet al.: Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy.Clin. Infect. Dis.40, 794–799(2005).
- Blázquez Garrido RM , EspinosaParra FJ, AlemanyFrancés Let al.: Antimicrobial chemotherapy for Legionnaires disease: levofloxacin versus macrolides. Clin. Infect. Dis.40, 800–806(2005).
- West M , BoulangerBR, FogartyCet al.: Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study.Clin. Ther.25, 485–506(2003).
- Centers for Disease Control and Prevention: Pneumonia and influenza death rates United States. MMWR Morb. Mortal. Wkly Rep.535–537(1995).
- Fein AM : Pneumonia in the elderly: overview of diagnostic and therapeutic approaches.Clin. Infect. Dis.28, 726–729(1999).
- El-Solh AA , PietrantoniC, BhatAet al.: Microbiology of severe aspiration pneumonia in institutionalized elderly.Am. J. Respir. Crit. Care Med.167, 1650–1654(2003).
- Niederman MS , MandellLA, AnzuetoAet al.: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care Med.163, 1730–1754(2001).
- Mandell LA , BartlettJG, DowellSF, File TM Jr, Musher DM, Whitney C: Update of Practice Guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin. Infect. Dis.37, 1405–1433(2003).
- BTS Guidelines for the management of community acquired pneumonia in adults. Thorax56(Suppl. 4), S1–S64 (2001).
- Mandell LA , MarrieTJ, GrossmanRF, ChowAW, HylandRH: Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group.Clin. Infect. Dis.31, 383–421(2000).
- Goldberg J , OwensRC Jr: Optimizing antimicrobial dosing in the critically ill patient. Curr. Opin. Crit. Care8, 435–440(2002).
- Nicolle LE : Quinolones in the aged.Drugs58(Suppl. 2), 49–51(1999).
- Stahlmann R , LodeH: Fluoroquinolones in the elderly: safety considerations.Drugs Aging20, 289–302(2003).
- Muto CA , PokrywkaM, ShuttKet al.: A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use.Infect. Control Hosp. Epidemiol.26, 273–280(2005).
- McCusker ME , HarrisAD, PerencevichE, Roghmann M-C: Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerging Infect. Dis.9, 730–733(2003).
- Edlund C , NordCE: Effect of quinolones on intestinal ecology.Drugs58(Suppl. 2), 65–70(1999).
- Cappelletty DM , SpiveyM, KhashabMM, KahnJB: The safety of levofloxacin 750 mg in elderly patients with community-acquired respiratory tract infections.American Thoracic Society International Meeting, San Diego, CA, USA (2005) (Abstract 4241).
- Cely CM , AroraP, QuartinAA, KettDH, ScheinRM: Relationship of baseline glucose homeostasis to hyperglycemia during medical critical illness.Chest126, 879–887(2004).
- Kagansky N , LevyS, RimonEet al.: Hypoglycemia as a predictor of mortality in hospitalized elderly patients.Arch. Intern. Med.163, 1825–1829(2003).
- Shilo S , BerezovskyS, FriedlanderY, SonnenblickM: Hypoglycemia in hospitalized nondiabetic older patients.J. Am. Geriatr. Soc.46, 978–982(1998).
- Mohr JF , McKinnonPS, PeymannPJ, KentonI, SeptimusE, OkhuysenPC: A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone.Pharmacotherapy25, 1303–1309(2005).
- Graumlich JF , HabisS, AvelinoRRet al.: Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.Pharmacotherapy25, 1296–1302(2005).